Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Mavenclad (cladribine tablets) for the Treatment of Relapsing-Remitting Multiple Sclerosis

Drug (Brand/Generic)

Mavenclad™/cladribine

Developed by

Merck Group

Therapy Class

Selective immune reconstitution therapy

Current Indication

Multiple sclerosis

Market Sector

CNS

Development Status

Approved in Canada, Australia and Europe
Expand

Go Top